Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial

Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial

Abstract Cancer of unknown primary has a dismal prognosis, especially following failure of platinum-based chemotherapy. 10-20% of patients have a high tumor mutational burden (TMB), which predicts response to immunotherapy in many cancer types. In this prospective, non-randomized, open-label, multic...

Full description

Bibliographic Details
Main Authors: Maria Pouyiourou, Bianca N. Kraft, Timothy Wohlfromm, Michael Stahl, Boris Kubuschok, Harald Löffler, Ulrich T. Hacker, Gerdt Hübner, Lena Weiss, Michael Bitzer, Thomas Ernst, Philipp Schütt, Thomas Hielscher, Stefan Delorme, Martina Kirchner, Daniel Kazdal, Markus Ball, Klaus Kluck, Albrecht Stenzinger, Tilmann Bochtler, Alwin Krämer
Format: Article
Language:English
Published: Nature Portfolio 2023-10-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-023-42400-5

Internet

https://doi.org/10.1038/s41467-023-42400-5

Similar Items